中華新聞通訊社/中華時報11月14日訊（記者袁毅強)摘要： 2025 年 11 月在泰國曼谷舉行的「We Are the World Bangkok 2025」峰會，彙集了全球生物健康、AI 創新與傳統醫學的頂尖力量。會議不僅展示了再生醫學、癌症及長壽醫學領域的突破性治療潛力，並特別引入劉保池團隊利用自體骨髓幹細胞治療肝臟和胰腺疾病的具體臨床案例，更成為一場關於地緣政治、醫療倫理與監管哲學的深度交鋒。文章旨在剖析亞洲成為全球醫療整合樞紐的戰略雄心，同時揭示在跨國「同情治療」框架下，創新商業化與患者知情同意真實性所面臨的系統性挑戰。
一、峰會背景、主旨與組織理念
2025 年 11 月，「We Are the World Bangkok 2025：全球生物健康、AI 創新與傳統醫學融合峰會」在泰國曼谷詩麗吉王后國家會議中心（QSNCC）舉行。峰會宗旨為「促進全球生物健康、人工智慧及傳統醫療融合」，並著重於探討亞洲在全球醫療創新與臨終關懷領域的新定位與角色。
名譽主席鄭志剛博士（Adrian Cheng）強調，亞洲正處於醫療創新轉型的關鍵節點，倡議香港及亞洲應成為全球醫療合作的新樞紐，建立跨國醫療科技合作平臺及可信賴的健康科技交流通道。創辦人Michael Chin與Josephine Ko則強調，平臺旨在打破**「資訊壁壘」，建立「可信資訊的入口」，支持患者的自主權（Patient Autonomy）**。
二、創新與監管的觀點碰撞：為希望設定邊界
本次峰會的核心挑戰在於如何劃定醫療創新與監管的邊界。與會者對於未批准療法商業化的態度呈現出顯著分歧：
創新支持者： 拿督陳革成教授（Dato’ Prof. Dr. Mike Chan）明確主張，當傳統醫學無法再提供希望時，創新療法應該被允許在嚴格監督下嘗試，強調患者有權選擇治療。
學界與監管界： 泰國前衛生部副部長 Phinij Jarusombat 提出警惕，認為監管與倫理必須同步重視。香港中醫藥大學研究員 王清博士 則指出，實驗性療法若未經批准，應僅限於臨床研究環境，而非市場收費使用。
科技界： 人工智慧醫療企業家 Arun Ratanakul 博士（泰國） 呼籲採用**「動態監管機制」（dynamic regulation）和「分級監管」（tiered regulation）**，以避免創新被過度延遲。
病患與倫理團體： Chalida Prasert 女士 和 Prof. Lim Choon Wah 共同發出警告，警惕**「希望商品化」，強調同情使用絕不等於商業化授權，必須公開監管與成本細節**。
三、焦點議題：再生醫學的實踐案例與灰色地帶
峰會的議題深度延伸至再生醫學、癌症和長壽醫學，強調結合傳統醫學、生物科技和 AI 的實驗性治療方案。
- 再生醫學的代表案例：劉保池團隊的自體幹細胞修復方案
來自上海公共衛生的劉保池博導團隊提供的治療方案，為再生醫學的潛力提供了具體的學術案例。其核心是利用患者自身的**自體骨髓幹細胞（ABMI/ABMNCs）**作為「修復工具」。
治療機制與目標： 這些幹細胞通過手術（如網膜靜脈/動脈）或微創的 B 超引導注射，被輸送到受損的肝臟和/或胰腺。目的是讓幹細胞分化成功能細胞或分泌修復因數，從而修復肝功能（如降低腹水和膽紅素、提高白蛋白）和改善糖尿病病情（如降低血糖和糖化血紅蛋白）。
技術優勢： 微創注射的優勢在於創傷小、無需住院且依從性高，體現了當前精准微創介入治療的發展趨勢。
- 癌症、長壽醫學與新興視角
癌症與慢性病的突破性治療： 專家群體主張通過整合醫學尋找癌症、帕金森氏症等慢性病的治癒方案，挑戰傳統的症狀管理模式。
長壽醫學與抗衰老研究： 討論聚焦於延長健康壽命（Health Span），探討了如**雷帕黴素（Rapamycin）**等具抗衰老潛力的藥物研究，並強調實現長壽需結合生活方式干預。
幹細胞療法的灰色地帶： 儘管劉團隊的方案提供了樂觀前景，但國際醫學界仍普遍共識：未獲得藥品或醫療技術批准的療法，不得以收費治療形式進行，呼籲對此類未批准療法的商業化保持高度警惕。
四、深度分析：地緣政治與跨國倫理挑戰
將亞洲定位為全球醫療整合的新樞紐，具有深遠的政治與經濟意涵，同時也暴露了現有倫理法律框架的不足。
- 亞洲醫療樞紐的戰略意義
將亞洲打造成醫療整合策源地，反映了區域內國家對高附加值醫療產業的主導權爭奪。傳統醫學的國際化是提升亞洲醫療軟實力的戰略舉措。然而，這種競爭也帶來了**法規套利（Regulatory Arbitrage）**的風險，即不肖機構可能利用亞洲各國監管差異，尋找最寬鬆的環境進行實驗性療法的商業化，從而損害區域的集體聲譽。
- 「同情治療」的倫理與法律盲點
會議的核心爭議體現了現有法律與倫理框架的不足。
知情同意的真實性挑戰： 在末期病患面臨巨大心理壓力、時間緊迫和高昂治療費用時，他們所給予的「知情同意」是否真正具備自主性與非脅迫性，成為嚴肅的倫理問題。當「希望」被高度商品化時，患者的**脆弱性（Vulnerability）**可能被利用。
同情治療與商業化界限模糊： 跨國私人機構以「同情治療」為名收取高額「服務費」的行為，實際上模糊了治療與商業推廣的界限。這要求亞洲建立一個統一且獨立的跨國倫理審查機制，特別針對涉及收費的未批准療法，以確保營利動機不主導病患的治療決策。
五、結語：邁向倫理共識的轉譯通道
峰會的實驗性國際對話最終指向一個共同目標：建立一條安全且透明的**「轉譯通道」（Translational Pathway），將嚴謹的臨床研究結果轉化為負責任的實際應用。這需要亞洲不僅在技術上保持領先，更要在區域性醫療創新倫理與監管協作框架**的建立上達成共識。只有平衡好患者獲取創新療法的權利與其作為弱勢群體被保護的權利，才能確保亞洲成為一個真正可信賴的全球醫療整合樞紐。
We Are the World Bangkok 2025: International Summit on Innovation, Regulatory Boundaries, and Patient Empowerment
ChinaTimes Nov. 14, 2025, Bangkok By YIQIANG YUAN
Summary: The “We Are the World Bangkok 2022” Summit in Bangkok in November 2025 gathered leading forces in global biohealth, AI innovation, and traditional medicine. The conference not only showcased the breakthrough potential in regenerative medicine, cancer, and longevity medicine—notably including the specific clinical case of Professor Liu Baochi’s team utilizing Autologous Bone Marrow Stem Cells for liver and pancreas repair—but also served as a profound arena for the convergence of geopolitics, medical ethics, and regulatory philosophy. This analysis dissects Asia’s strategic ambition to advance global healthcare integration while exposing the systemic challenges related to commercializing innovation and the authenticity of informed consent under the cross-border “compassionate care” framework.
- Summit Background, Mandate, and Organizational Philosophy
The “We Are the World Bangkok 2025: Global Biohealth, AI Innovation & Traditional Medicine Fusion Cooperation Summit” was held at the Queen Sirikit National Convention Center (QSNCC) in Bangkok in November 2025. The summit’s mandate was to “promote the fusion of global biohealth, artificial intelligence, and traditional medicine,” emphasizing Asia’s evolving role in global medical innovation and end-of-life care.
Honorary Chairman Dr. Adrian Cheng stressed that Asia is at a crucial inflection point, advocating for the region to become the new global hub for medical cooperation by establishing trustworthy, verifiable health technology exchange channels. Founders Michael Chin and Josephine Ko emphasized the platform’s role in dismantling the “information barrier,” establishing a “credible information portal,” and supporting Patient Autonomy.
- The Clash of Perspectives: Setting Boundaries for Hope
The core challenge lay in defining the boundaries between innovation and regulation, with distinct viewpoints on the commercialization of unapproved therapies:
Innovation Advocates: Dato’ Prof. Dr. Mike Chan asserted that when conventional medicine can no longer offer hope, innovative therapies should be permitted under strict supervision, emphasizing the patient’s right to choose treatment.
Academia and Regulatory Bodies: Phinij Jarusombat cautioned that regulation and ethics must be equally prioritized. Dr. Wang Qing stated that experimental therapies, if unapproved, must be restricted exclusively to the clinical research environment, not utilized for commercial, fee-for-service purposes.
Technology Sector: Dr. Arun Ratanakul argued for a “Dynamic Regulation” mechanism and “Tiered Regulation” to prevent innovation from being unduly delayed.
Patient and Ethics Groups: Ms. Chalida Prasert and Prof. Lim Choon Wah warned against the “commodification of hope,” stressing that regulatory and cost details must be transparently disclosed, as compassionate use is not synonymous with commercial authorization.
III. Focal Points: Regenerative Medicine Case Studies and the Grey Zone
The summit extensively covered regenerative medicine, cancer, and longevity, highlighting experimental therapies combining traditional medicine, biotech, and AI.
- Regenerative Medicine Case Study: Professor Liu Baochi’s Autologous Stem Cell Repair
The treatment approach developed by Professor Baochi Liu’s team from Shanghai Public Health provides a specific academic example of regenerative potential. The core mechanism is the use of the patient’s own Autologous Bone Marrow Stem Cells (ABMI/ABMNCs) as a “repair tool.”
Mechanism and Objectives: These stem cells are delivered to the damaged liver and/or pancreas either through surgical routes (e.g., Reticular Omentum Vein/Artery) or via a minimally invasive B-ultrasound-guided injection. The goal is for the stem cells to differentiate into functional cells or secrete repair factors, thereby improving liver function (e.g., reducing ascites and total bilirubin, increasing albumin) and ameliorating diabetes symptoms (e.g., lowering FBG and HbA1c).
Technical Advantage: The minimally invasive approach is emphasized for its low trauma, lack of required hospitalization, and high patient compliance, reflecting a modern trend toward precise, micro-invasive interventional therapies.
- Cancer, Longevity Medicine, and Emerging Perspectives
Breakthrough Treatment for Cancer & Chronic Disease: Experts advocated for Integrated Medicine to find curative solutions for conditions like Cancer and Parkinson’s, challenging traditional symptom management.
Longevity Medicine Research: Discussions centered on extending the Health Span, exploring anti-aging research into drugs like Rapamycin, and emphasizing the necessity of combining pharmaceuticals with lifestyle changes.
The Regulatory Grey Zone: Despite promising cases like the Liu team’s work, the consensus remains that unapproved therapies cannot be offered on a fee-for-service basis, urging vigilance against the commercialization of unapproved treatments.
- Deep Analysis: Geopolitics and Cross-Border Ethical Challenges
Positioning Asia as a global healthcare hub carries profound geopolitical and economic implications, exposing critical gaps in existing ethical and legal frameworks.
- Strategic Significance of the Asian Healthcare Hub
The drive reflects regional competition for dominance in the high-value healthcare industry. TCM internationalization enhances Asia’s medical soft power. However, this competition introduces the risk of Regulatory Arbitrage, where entities exploit national regulatory discrepancies to commercialize experimental therapies, potentially damaging the region’s collective reputation.
- Ethical and Legal Blind Spots in “Compassionate Care”
Authenticity of Informed Consent: When terminally ill patients face immense pressure and high costs, the voluntariness and non-coerciveness of their “informed consent” is ethically questionable. When “hope” is highly commercialized, the patient’s vulnerability is at risk of exploitation.
Blurred Commercial Boundaries: Charging high “service fees” for unapproved treatments under “compassionate care” substantively circumvents ethical principles. This necessitates the creation of a unified, independent cross-border ethical review mechanism in Asia to ensure profit motives do not dictate patient treatment decisions.
- Conclusion: Towards a Translational Pathway of Ethical Consensus
The summit’s international dialogue points toward the shared goal of establishing a safe and transparent “Translational Pathway” to convert rigorous research into responsible practice. This requires Asia to achieve consensus on a Regional Framework for Ethical and Regulatory Collaboration in Medical Innovation. Only by balancing the patient’s right to access innovative therapies with their right to protection as a vulnerable population can Asia secure its status as a truly trustworthy global healthcare integration hub.